Skip to Main Content

Paper Details

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
Neurology: Neuroimmunology and NeuroInflammation
23
2023
EDSS, GFAP, MS, Multiple Sclerosis, Neurodegeneration, NfL, Patients, brain/spinal cord lesions, glial, multiple sclerosis, patients, sGFAP, sNfL, serum neurofilament light chain
Author NameAffiliation
Howard L WeinerFrom the Harvard Medical School (C.B., T.C.) Ann Romney Center for Neurologic Diseases (C.B., Brigham and Women's Hospital Brigham Multiple Sclerosis Center (R.B., Brigham and Women's Hospital Center for Neurological Imaging (C.R.G.G.), Brigham and Women's Hospital Biostatistics Center (B.C.H.), Massachusetts General Hospital, MA and Novartis Pharma AG (H.K.)
  • 1 - 1

Datasets